Page last updated: 2024-09-04

dx 8951 and Peritoneal Neoplasms

dx 8951 has been researched along with Peritoneal Neoplasms in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bastien, L; De Jager, R; Duggal, A; Hu, W; Kavanagh, JJ; Kudelka, AP; Loyer, E; Verschraegen, CF; Vincent, M1
Bevers, M; Kavanagh, JJ; Kudelka, AP; Levenback, C; Loyer, E; Verschraegen, CF; Vincent, M; Wolf, J1

Trials

2 trial(s) available for dx 8951 and Peritoneal Neoplasms

ArticleYear
A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan.
    Cancer chemotherapy and pharmacology, 2004, Volume: 53, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Bridged-Ring Compounds; Camptothecin; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Peritoneal Neoplasms; Taxoids; Topotecan

2004
Phase II study of intravenous DX-8951f in patients with advanced ovarian, tubal, or peritoneal cancer refractory to platinum, taxane, and topotecan.
    Annals of the New York Academy of Sciences, 2000, Volume: 922

    Topics: Antineoplastic Agents, Phytogenic; Bridged-Ring Compounds; Camptothecin; Drug Administration Schedule; Drug Resistance, Multiple; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum Compounds; Taxoids; Topotecan

2000